Remove 2010 Remove Drug Pricing Remove Vaccines
article thumbnail

Unpleasant truth: the pandemic, record debt and our opportunity for sustainability

pharmaphorum

When the day hopefully comes where a vaccine is widely available, we will be relieved of the great stress and uncertainty of this time. 4 Global oncology spending in 2010, 2015, and 2020, by region (in billion U.S. 6 Forbes, ‘Biologic Medicines: The Biggest Driver of Rising Drug Prices’. Touch Oncology.

article thumbnail

Streamlining bioprocessing for gene therapy

European Pharmaceutical Review

Single-use bioprocessing technologies enabling more rapid vaccines production [Internet]. Available from: [link] About the author Kai Lipinski, PhD joined Vibalogics, now ReciBioPharm, in 2010 as Head of Cell Culture and Virus Production. million for Hemgenix [AAV5-hFIX-Padua]). Innovation trends in Industrial Biotechnology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ESG Top Trends: Macroeconomic trends

Pharmaceutical Technology

According to the World Health Organization (WHO), two billion people lack access to essential or basic drugs. In 2010, only eight big pharma companies had an access strategy for low- and middle-income countries, but today, 17 of the biggest 20 companies do. Drug pricing and gouging.

article thumbnail

Medicare Price “Negotiations” Will Jeopardize Patient Access to New Medicines, Result in Worse Health Outcomes

Safe Biologics

September 11, 2023 The Centers for Medicare & Medicaid Services (CMS) recently announced the first 10 drugs selected under its Medicare drug price “negotiation” plan, authorized by the Inflation Reduction Act (IRA) signed in to law last year. 1] 90% of new cancer drugs are available in the U.S.

article thumbnail

STAT+: Pharmalittle: We’re reading about an activist investor stake in Pfizer, Trump backing off drug-pricing plan, and more

STAT

… Former President Trump is backing off his support for a controversial drug pricing plan that struck fear into the hearts of pharmaceutical executives during his first term , STAT reports. Meanwhile, we have assembled another menu of tidbits for you to peruse as you start another journey. Your cards and notes are appreciated.